Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(1 year, 10 months ago) | |
US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(3 years from now) | |
US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(2 years ago) | |
US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(7 years from now) | |
US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(8 years from now) | |
US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) | |
US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
New Indication(I-764) | Jan 24, 2021 |
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation
Dosage: TABLET;ORAL